|Dr. Erik Digman Wiklund||Chief Executive Officer||3.79M||N/A||N/A|
|Dr. Lubor Gaal Ph.D.||Chief Financial Officer||3.22M||N/A||1968|
|Dr. Victor Levitsky M.D., Ph.D.||Chief Scientific Officer||849k||N/A||N/A|
|Mr. Ola Melin||VP & Head of CMC||2.17M||N/A||N/A|
|Mr. Jon Amund Eriksen M.Sc., MSc||Special Advisor||1.86M||N/A||N/A|
|Prof. Gustav Gaudernack Ph.D.||Chief Scientific Adviser||N/A||N/A||N/A|
|Dr. Thomas Birkballe Hansen||VP & Head of Research||N/A||N/A||N/A|
|Dr. Peter Skorpil Ph.D.||Vice President of Business Development||1.07M||N/A||N/A|
Circio Holding ASA, a clinical stage cancer immunotherapy and RNA therapeutics company. Its lead product candidate is ONCOS-102 for the treatment of mesothelioma and melanoma cancer. The company is also developing TG-01, a cancer vaccine program based on neoantigen vaccine for mutant KRAS cancers; and ONCOS immunotherapy technologies to stimulate the immune system. The company has collaboration agreement with the University of Kansas Cancer Center, as well as a research collaboration with Neoregen Biotech to develop novel NICT-delivered circVec therapeutic candidates. The company was formerly known as Targovax ASA and changed its name to Circio Holding ASA in May 2023. Circio Holding ASA was incorporated in 2010 and is based in Lysaker, Norway.
Circio Holding ASA’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.